Sponsors (2)
The bill increases transparency, procedural predictability for sponsors, and targeted flexibility (especially for rare-disease drugs) and modestly funds pediatric research, but does so at the cost of weakening or delaying some enforcement levers and reducing incentives to generate pediatric evidence — shifting risks and decision burdens onto clinicians, families, and some children.
Patients (especially children) and the public gain greater transparency and accountability because the FDA must track and publicly report whether pediatric study deferrals and penalties/settlements are completed and paid, creating stronger public incentives for sponsors to comply.
Rare-disease patients (and their families) may get faster access to adult-approved orphan drugs and face lower trial burdens because the bill clarifies waivers/deferrals, creates an automatic-waiver list, and allows use of real-world evidence for pediatric labeling.
Drug applicants/holders receive stronger procedural protections and regulatory predictability — including required notice and a 45-day response window, limited retroactive enforcement for certain failures, and protection for products no longer marketed — reducing the risk of sudden penalties.
Children (and other patients) face a material risk of delayed or reduced pediatric safety/efficacy data because the bill limits enforcement tools (including limits on section 303), provides response and transition windows, and narrows when FDA can compel studies — weakening the agency's leverage to ensure timely pediatric trials.
For rare diseases, reduced mandatory pediatric study requirements and expanded waiver/deferral paths may lower incentives for companies to generate pediatric evidence, increasing off-label prescribing and shifting clinical/financial burdens onto families and healthcare providers.
Centralizing up to ~1% of institute pediatric budgets could reduce funding for locally prioritized projects and shift research priorities away from some patient populations or niche programs.
Based on analysis of 5 sections of legislative text.
Modifies FDA enforcement and reporting for pediatric-study requirements, allows small NIH pediatric fund transfers into a pediatric studies program, and narrows pediatric requirements for orphan-designated drugs pending new guidance.
Official title: Amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.
Introduced February 25, 2025 by John F. Reed · Last progress February 25, 2025
Changes how the FDA enforces and reports on pediatric study requirements, shifts small amounts of NIH pediatric research funding into a centralized pediatric studies program for FY2026–FY2030, and narrows how orphan-designated drugs are treated under pediatric-assessment rules. The bill adds procedural protections before enforcement (a required noncompliance letter, 45-day response window, and a due-diligence review), limits use of certain civil enforcement for unmarketed products and pre-enactment failures, requires new FDA reporting on pediatric compliance and penalties, authorizes limited NIH fund transfers to a pediatric studies program, and directs the FDA to issue guidance and hold a public meeting about applying pediatric requirements to orphan-designated products.